Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPOS Study
2022-502378-17-00Phase 2Completed
- Sponsor
- Keros Therapeutics
- Start
- Feb 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing KER-012 (cibotercept) plus background PAH therapy with Placebo plus background PAH therapy (2 arms). Primary endpoint: Change from Baseline in pulmonary vascular resistance (PVR) at Week 24. Started Feb 2024; status: completed.
02
Drugs
cibotercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2022-502378-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502378-17-00.